Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/1997

01-01-1997

P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer

Authors: Hyun Cheol Chung, Sun Young Rha, Joo Hang Kim, Jae Kyung Roh, Jin Sik Min, Kyung Sik Lee, Byung Soo Kim, Kyi Beom Lee

Published in: Breast Cancer Research and Treatment | Issue 1/1997

Login to get access
Metadata
Title
P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer
Authors
Hyun Cheol Chung
Sun Young Rha
Joo Hang Kim
Jae Kyung Roh
Jin Sik Min
Kyung Sik Lee
Byung Soo Kim
Kyi Beom Lee
Publication date
01-01-1997
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/1997
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1005739525196

Other articles of this Issue 1/1997

Breast Cancer Research and Treatment 1/1997 Go to the issue

OriginalPaper

Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis

OriginalPaper

Seasonal variation in the secretion of mammotrophic hormones in normal women and women with previous breast cancer

OriginalPaper

Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer

OriginalPaper

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

OriginalPaper

Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells

OriginalPaper

Epidermal growth factor in plasma and saliva of patients with active breast cancer and breast cancer patients in follow-up compared with healthy women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits